Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799396 · ClinicalTrials.gov registry record · Phase 4
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 682
- Enrollment target
NCT00799396 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 682 participants.
The verdict
NCT00799396, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 682 participants
- Enrollment target
Study Summary
One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications. The variance in treatment response may be linked to genetics. This study will examine the effects of aspirin and clopidogrel in a population whose genes are well known in order to determine the role that genes play in treatment responses.
Interventions
- DRUG Aspirin
- DRUG Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2006-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799396
The ClinicalTrials.gov registry entry for NCT00799396 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT00799396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799396 about?
NCT00799396 is a clinical study titled "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)". One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications. The variance in treatment response may be linked to genetics. This study will examine the effects of aspirin and cl...
What is the current status of trial NCT00799396?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 682 participants. The study started on 2006-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00799396?
The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00799396?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.